HRP20190633T1 - Postupci i pripravci za inhibiciju integrina upotrebom spojeva koji sadrže telurij - Google Patents
Postupci i pripravci za inhibiciju integrina upotrebom spojeva koji sadrže telurij Download PDFInfo
- Publication number
- HRP20190633T1 HRP20190633T1 HRP20190633TT HRP20190633T HRP20190633T1 HR P20190633 T1 HRP20190633 T1 HR P20190633T1 HR P20190633T T HRP20190633T T HR P20190633TT HR P20190633 T HRP20190633 T HR P20190633T HR P20190633 T1 HRP20190633 T1 HR P20190633T1
- Authority
- HR
- Croatia
- Prior art keywords
- tellurium
- eye
- neovascularization
- compound
- general formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 12
- 229910052714 tellurium Inorganic materials 0.000 title claims 7
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 title claims 7
- 108010044426 integrins Proteins 0.000 title claims 4
- 102000006495 integrins Human genes 0.000 title claims 4
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- -1 hydroxy, thiohydroxy Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- LAJZODKXOMJMPK-UHFFFAOYSA-N tellurium dioxide Chemical compound O=[Te]=O LAJZODKXOMJMPK-UHFFFAOYSA-N 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010015943 Eye inflammation Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010065630 Iris neovascularisation Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 1
- 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102100022337 Integrin alpha-V Human genes 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 102100025390 Integrin beta-2 Human genes 0.000 claims 1
- 102100032999 Integrin beta-3 Human genes 0.000 claims 1
- 102100033011 Integrin beta-6 Human genes 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 101000935036 Ovis aries Integrin beta-1 Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D517/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D329/00—Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Upotreba barem jednog spoja koji sadrži telurij za pripravu lijeka za liječenje bolesti oka ili poremećaja naznačenog time što je neovaskularizacija oka;
pri čemu je navedeni barem jedan spoj koji sadrži telurij odabran iz skupine koju čine telurijev dioksid (TeO2), kompleks TeO2,
spoj koji ima opću Formulu I:
spoj koji ima opću Formulu II:
spoj koji ima opću Formulu III:
i
spoj koji ima opću Formulu IV:
pri čemu:
svaki od t, u i v je neovisno 0 ili 1;
svaki od m i n je neovisno 0, 1, 2 ili 3;
Y je odabran iz skupine koju čine amonij, fosfonij, kalij, natrij i litij;
X je halogeni atom; i
svaki od R1-R22 je neovisno odabran iz skupine koju čine vodik, hidroksialkil, hidroksi, tiohidroksi, alkil, alkenil, alkinil, alkoksi, tioalkoksi, halogen, haloalkil, karboksi, karbonil, alkilkarbonilalkil, karboksialkil, acil, amido, cijano, N-monoalkilamidoalkil, N,N-dialkilamidoalkil, cijanoalkil, alkoksialkil, karbamil, cikloalkil, heteroaliciklički, sulfonil, sulfinil, sulfat, amin, aril, heteroaril, fosfat, fosfonat i sulfonamido.
2. Upotreba prema zahtjevu 1, naznačena time što navedeni spoj koji sadrži telurij inhibira integrin koji obuhvaća integrinsku podjedinicu αV, β1, β2, β3 ili β6.
3. Upotreba prema zahtjevu 2, naznačena time što navedeni integrin je αvβ3 integrin ili VLA-4.
4. Upotreba prema zahtjevu 1, naznačena time što navedeni spoj koji sadrži telurij ima opću Formulu I.
5. Upotreba prema zahtjevu 1, naznačena time što t, u i v su svaki 0 i pri čemu svaki od R1, R8, R9 i R10 je vodik, pri čemu X je klor i pri čemu Y je amonij.
6. Upotreba prema zahtjevu 1, naznačena time što navedeni spoj ima opću Formulu IV, pri čemu svaki od m i n je 0 i pri čemu svaki od R15, R18, R19 i R22 je vodik.
7. Upotreba prema bilo kojem od zahtjeva 1-6, naznačena time što je navedena bolest ili poremećaj oka dijabetička retinopatija, retinopatija nedonoščeta, neovaskularni glaukom, retinoblastom, retrolentalna fibroplazija, rubeoza, uveitis, makularna degeneracija, bolest povezana s koroidnom neovaskularizacijom ili neovaskularizacija irisa, neovaskularizacija presatka rožnice, upala oka ili tumor oka.
8. Barem jedan spoj koji sadrži telurij prema bilo kojem od zahtjeva 1-6, za uporabu u liječenju bolesti oka ili poremećaja naznačen time što obuhvaća neovaskularizaciju oka kod subjekta.
9. Barem jedan spoj koji sadrži telurij za uporabu prema zahtjevu 8, naznačen time što je navedena bolest ili poremećaj oka dijabetička retinopatija, retinopatija nedonoščeta, neovaskularni glaukom, retinoblastom, retrolentalna fibroplazija, rubeoza, uveitis, makularna degeneracija, bolest povezana s koroidnom neovaskularizacijom ili neovaskularizacija irisa, neovaskularizacija presatka rožnice, upala oka ili tumor oka.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99654807P | 2007-11-23 | 2007-11-23 | |
| EP14173546.4A EP2826371B1 (en) | 2007-11-23 | 2008-11-23 | Methods and compositions for inhibiting integrins using tellurium-containing compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190633T1 true HRP20190633T1 (hr) | 2019-08-23 |
Family
ID=40667929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190633TT HRP20190633T1 (hr) | 2007-11-23 | 2019-04-02 | Postupci i pripravci za inhibiciju integrina upotrebom spojeva koji sadrže telurij |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100297256A1 (hr) |
| EP (2) | EP2222167A4 (hr) |
| CA (1) | CA2705944C (hr) |
| DK (1) | DK2826371T3 (hr) |
| HR (1) | HRP20190633T1 (hr) |
| LT (1) | LT2826371T (hr) |
| SI (1) | SI2826371T1 (hr) |
| WO (1) | WO2009066300A2 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010146585A1 (en) * | 2009-06-16 | 2010-12-23 | Biomas Ltd. | Tellurium-containing compounds for treating viral infections |
| JP2018506589A (ja) * | 2015-02-26 | 2018-03-08 | フェラムダ リミテッド | 血管形成疾患および障害を治療するための組成物および組み合わせ |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102908A (en) | 1985-03-15 | 1992-04-07 | Michael Albeck | Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives |
| US4962207A (en) * | 1985-09-30 | 1990-10-09 | Bar-Ilan University | Organic derivatives of tellurium and selenium |
| US4761490A (en) * | 1985-03-15 | 1988-08-02 | Bar-Ilan University | Organic derivatives of tellurium and selenium and their use to stimulate cytokine production |
| US4764461A (en) * | 1985-09-30 | 1988-08-16 | Bar-Ilan University | Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines |
| US4752614A (en) * | 1985-09-30 | 1988-06-21 | Bar-Ilan University | Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines |
| US5093135A (en) | 1985-09-30 | 1992-03-03 | Michael Albeck | Compounds for the induction of in vivo and in vitro production of cytokines |
| US4929739A (en) * | 1988-03-24 | 1990-05-29 | Bar-Ilan University | Complexes of tellurium and selenium derivatives |
| US5213899A (en) | 1990-12-17 | 1993-05-25 | General Electric Company | Room temperature vulcanizable silicone compositions |
| WO2005060341A2 (en) * | 2003-12-18 | 2005-07-07 | Biomas, Ltd | Tellurium derivatives for prevention and treatment of neurodegenerative processes |
| ES2465498T3 (es) * | 2004-01-22 | 2014-06-05 | Biomas Ltd. | Procedimientos terapéuticos y composiciones farmacéuticas de tratamiento de verrugas con compuestos de teluro |
| US20080260770A1 (en) * | 2004-09-17 | 2008-10-23 | Biomas Ltd. | Use of Tellurium Compounds as Adjuvants |
| CA2580642C (en) | 2004-09-17 | 2014-09-02 | Biomas, Ltd. | Novel tellurium compounds and their use as immunomodulators |
| WO2008032227A2 (en) * | 2006-09-11 | 2008-03-20 | Biomas, Ltd. | Topical formulations of tellurium-containing compounds |
-
2008
- 2008-11-23 DK DK14173546.4T patent/DK2826371T3/en active
- 2008-11-23 SI SI200832055T patent/SI2826371T1/sl unknown
- 2008-11-23 EP EP08852795A patent/EP2222167A4/en not_active Withdrawn
- 2008-11-23 EP EP14173546.4A patent/EP2826371B1/en active Active
- 2008-11-23 WO PCT/IL2008/001537 patent/WO2009066300A2/en active Application Filing
- 2008-11-23 CA CA2705944A patent/CA2705944C/en not_active Expired - Fee Related
- 2008-11-23 US US12/744,329 patent/US20100297256A1/en not_active Abandoned
- 2008-11-23 LT LTEP14173546.4T patent/LT2826371T/lt unknown
-
2014
- 2014-03-13 US US14/208,104 patent/US20140194496A1/en not_active Abandoned
-
2019
- 2019-04-02 HR HRP20190633TT patent/HRP20190633T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140194496A1 (en) | 2014-07-10 |
| US20100297256A1 (en) | 2010-11-25 |
| EP2222167A4 (en) | 2011-01-05 |
| WO2009066300A3 (en) | 2010-03-11 |
| EP2826371A2 (en) | 2015-01-21 |
| EP2826371A3 (en) | 2015-12-30 |
| CA2705944A1 (en) | 2009-05-28 |
| LT2826371T (lt) | 2019-06-25 |
| EP2826371B1 (en) | 2019-01-02 |
| WO2009066300A2 (en) | 2009-05-28 |
| DK2826371T3 (en) | 2019-04-23 |
| EP2222167A2 (en) | 2010-09-01 |
| SI2826371T1 (sl) | 2019-09-30 |
| CA2705944C (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190633T1 (hr) | Postupci i pripravci za inhibiciju integrina upotrebom spojeva koji sadrže telurij | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2015025011A5 (hr) | ||
| HRP20220740T1 (hr) | Postupci za liječenje virusnih infekcija arenaviridae | |
| RS53065B (en) | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| CL2008003120A1 (es) | Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras. | |
| HRP20150419T1 (hr) | Ko-kristali i soli od ccr3-inhibitora | |
| HRP20190561T1 (hr) | Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom | |
| JP2011506438A5 (hr) | ||
| PE20130242A1 (es) | Derivados de isoxazolo-piridina | |
| PH12014501719A1 (en) | Pyridone derivatives | |
| JP2016506960A5 (hr) | ||
| NZ712180A (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis | |
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| RS51394B (en) | SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS | |
| JP2013500314A5 (hr) | ||
| NZ603594A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
| ME01617B (me) | Dugotrajno tretiranje hiv-infekcije s tcm278 | |
| HRP20120867T1 (hr) | Selurampanel | |
| BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende |